Logo

Sanofi Reports the P-II Study Data of Frexalimab for the Treatment of Multiple Sclerosis

Share this
Sanofi

Sanofi Reports the P-II Study Data of Frexalimab for the Treatment of Multiple Sclerosis

Shots:

  • The P-II study assessed frexalimab in relapsing MS patients administered with either high dose (1200mg, IV, Q4W with 1800mg loading dose) or low dose (300mg, SC, Q2W with 600mg loading dose) vs matching PBO for 12wks. (part A). P-III trials for relapsing MS & non-relapsing secondary progressive MS has initiated recruitment
  • In the study, 97% of them from 12wk. treatment proceeded to OLE P-II study with 87% remaining by the 48wk. Results showed reduced plasma NfL levels by 41% (high-dose) & 35% (low-dose) from baseline to wk.48
  • Moreover, patients had 24% (switched to high dose) & 33% (switched to low dose) reduced plasma NfL levels at wk.12 from baseline to wk.48 with 39% after wk.12 in both

Ref: Globenewswire | Image: Sanofi

Related News:- Sanofi to Highlight New Data from the P-II Study of Frexalimab for the Treatment of Multiple Sclerosis at AAN 2024

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions